NO994398L - 2-Alkyliden-19-nor-vitamin D-forbindelser - Google Patents

2-Alkyliden-19-nor-vitamin D-forbindelser

Info

Publication number
NO994398L
NO994398L NO994398A NO994398A NO994398L NO 994398 L NO994398 L NO 994398L NO 994398 A NO994398 A NO 994398A NO 994398 A NO994398 A NO 994398A NO 994398 L NO994398 L NO 994398L
Authority
NO
Norway
Prior art keywords
compounds
vitamin
group
diseases
hydrogen
Prior art date
Application number
NO994398A
Other languages
English (en)
Other versions
NO994398D0 (no
NO322535B1 (no
Inventor
Hector F Deluca
Rafal R Sicinski
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25228793&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO994398(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Publication of NO994398D0 publication Critical patent/NO994398D0/no
Publication of NO994398L publication Critical patent/NO994398L/no
Publication of NO322535B1 publication Critical patent/NO322535B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO19994398A 1997-03-17 1999-09-10 2-Alkyliden-19-nor-vitamin D-forbindelser samt mellomprodukter for fremstilling derav NO322535B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/819,693 US5843928A (en) 1997-03-17 1997-03-17 2-alkylidene-19-nor-vitamin D compounds
PCT/US1998/002976 WO1998041501A1 (en) 1997-03-17 1998-02-11 2-alkylidene-19-nor-vitamin d compounds

Publications (3)

Publication Number Publication Date
NO994398D0 NO994398D0 (no) 1999-09-10
NO994398L true NO994398L (no) 1999-09-10
NO322535B1 NO322535B1 (no) 2006-10-23

Family

ID=25228793

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19994398A NO322535B1 (no) 1997-03-17 1999-09-10 2-Alkyliden-19-nor-vitamin D-forbindelser samt mellomprodukter for fremstilling derav

Country Status (14)

Country Link
US (2) US5843928A (no)
EP (1) EP0970047B1 (no)
JP (2) JP3786713B2 (no)
KR (1) KR100380914B1 (no)
AT (1) ATE223890T1 (no)
AU (1) AU714253B2 (no)
CA (1) CA2283829C (no)
DE (1) DE69807852T2 (no)
DK (1) DK0970047T3 (no)
ES (1) ES2179451T3 (no)
NO (1) NO322535B1 (no)
NZ (1) NZ337503A (no)
PT (1) PT970047E (no)
WO (1) WO1998041501A1 (no)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945410A (en) * 1997-03-17 1999-08-31 Wisconsin Alumni Research Foundation 2-alkyl-19-nor-vitamin D compounds
US6316642B1 (en) * 1997-03-17 2001-11-13 Wisconsin Alumni Research Foundation 26,27-Homologated-20-EPI-2alkyl-19-nor-vitamin D compounds
US6392071B1 (en) * 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
MA26481A1 (fr) * 1997-04-21 2004-12-20 Hoffmann La Roche Derives d'arylsecocholadiene
US5936105A (en) * 1997-06-13 1999-08-10 Tetrionics, Inc. 14-EPI-19-nor-vitamin D compounds and methods
US20030188756A1 (en) * 2002-08-19 2003-10-09 Cantorna Margherita T Treatment of inflammatory bowel disease with vitamin d compounds
US6359012B1 (en) * 1999-12-22 2002-03-19 Bone Care International, Inc. Method for making 24(S)-hydroxyvitamin D2
AU6527201A (en) * 2000-05-31 2001-12-11 Wisconsin Alumni Res Found 2-ethyl and 2-ethylidene-19-nor-vitamin d compounds
CN1217664C (zh) * 2000-07-14 2005-09-07 威斯康星校友研究基金会 2－亚甲基－19－去甲－20(S)－1α，25－二羟维生素D3增加骨强度的用途
JP4022144B2 (ja) 2000-09-08 2007-12-12 ウィスコンシン・アルムニ・リサーチ・ファウンデーション １アルファ−ヒドロキシ−２−メチレン−１９−ノル−ホモプレグナカルシフェロール及びその療法的適用
BR0207975A (pt) * 2001-03-15 2004-06-15 Basf Ag Composto, processo para preparar 5 fenilpiridinas, produto intermediário, agente adequado para combater fungos nocivos fitopatogênicos, e, processo para combater fungos nocivos fitopatogênicos
US6683219B2 (en) * 2001-07-30 2004-01-27 Wisconsin Alumni Research Foundation Synthesis of A-ring synthon of 19-nor-1α,25-dihydroxyvitamin D3 from (D)-glucose
US6835723B2 (en) * 2001-12-13 2004-12-28 Wisconsin Alumni Research Foundation 2-methylene-19-nor-20(S)-1α-hydroxy-bis-homo-pregnacalciferol in crystalline form
EP1453798B1 (en) * 2001-12-13 2008-10-15 Wisconsin Alumni Research Foundation (20s)-1alpha-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
US6627622B2 (en) 2002-02-18 2003-09-30 Wisconsin Alumni Research Foundation (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
US6566352B1 (en) 2002-02-18 2003-05-20 Wisconsin Alumni Research Foudation 1 α-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses
US6964784B2 (en) * 2002-03-07 2005-11-15 Optigenex, Inc. Method of preparation and composition of a water soluble extract of the bioactive component of the plant species uncaria for enhancing immune, anti-inflammatory, anti-tumor and dna repair processes of warm blooded animals
US20030195175A1 (en) * 2002-03-25 2003-10-16 Deluca Hector F. Use of carbon-2-modified-vitamin D analogs to induce the formation of new bone
WO2003084925A1 (en) * 2002-03-29 2003-10-16 Wisconsin Alumni Research Foundation METHOD OF SYNTHESIZING 1α-HYDROXY-2-METHYLENE-19-NOR-HOMOPREGNACALCIFEROL
US6846811B2 (en) * 2002-04-22 2005-01-25 Wisconsin Alumni Research Foundation (20S) 1α-hydroxy-2α-methyl and 2β-methyl-19-nor-vitamin D3 and their uses
US20080249068A1 (en) * 2002-09-05 2008-10-09 Deluca Hector F Method of Extending the Dose Range of Vitamin D Compounds
US7259143B2 (en) * 2002-09-05 2007-08-21 Wisconsin Alumni Research Foundation Method of extending the dose range of vitamin D compounds
WO2004076468A1 (ja) 2003-02-25 2004-09-10 Kobe Tennenbutsu Kagaku Kabushiki Kaisha ビタミンｄ誘導体を合成するための新規な中間体
EP1613588B1 (en) * 2003-04-10 2012-05-09 Wisconsin Alumni Research Foundation 2-propylidene-19-nor-vitamin d compounds
US6894037B2 (en) * 2003-07-03 2005-05-17 Wisconsin Alumni Research Foundation 2-methylene-19-nor-20(S)-25-methyl-1α-hydroxycalciferol and its uses
AU2004260642B2 (en) * 2003-07-03 2010-04-22 Wisconsin Alumni Research Foundation 2-methylene-19-nor-20(S)-25-methyl-1alpha-hydroxycalciferol and its uses
US20050009792A1 (en) * 2003-07-08 2005-01-13 Deluca Hector F. (20S)-1alpha-hydroxy-2-methylene-19-nor-vitamin D3 and its uses
US20050209203A1 (en) * 2003-07-30 2005-09-22 Jin Tian Use of vitamin Ds or vitamin D analogs to treat cardiovascular disease
WO2005018658A1 (en) * 2003-08-20 2005-03-03 Wisconsin Alumni Research Foundation 2-methylene-19-nor-vitamin d2 compounds
WO2005027918A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a cyclooxgenase-2 inhibitor
WO2005027921A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate
WO2005027915A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
WO2005027916A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and aromatase inhibitors
MXPA06003122A (es) * 2003-09-19 2006-05-31 Pfizer Prod Inc Composiciones farmaceuticas y procedimientos que comprenden combinaciones de derivados de 2-alquiliden-19-nor-vitamina d y un agonista/antagonista de estrogenos.
WO2005027925A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. 2-alkylidene-19-nor-vitamin d derivatives for the treatment of anorexia or low bone mass in females exhibiting aggressive athletic behavior
WO2005027928A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. 2-alkylidene-19-nor-vit amin d derivatives for the treatment of hypocalcemic tetany or hyproparathyroidism
WO2005027920A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. 2-alkylidene-19-nor-vitamin d derivatives for the treatment of rickets or vitamin d deficiency
WO2005027922A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. 2-alkylidene-19-nor-vitamin d derivatives for the treatment of hypogonadism or andropause
WO2005027931A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist
WO2005027913A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
WO2005027929A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen
WO2005027919A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. 2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture
WO2005027930A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. 2-alkylene-19-nor-vitamin d derivatives for the treatment of osteosarcoma
WO2005027926A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bone morphogenetic protein
NZ545632A (en) * 2003-09-19 2009-09-25 Wisconsin Alumni Res Found 2-Alkylidene-19-nor-vitamin D derivatives for the treatment of frailty, muscle damage or sarcopenia
WO2005027927A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. 2-alkylidene-19-nor-vitamin d derivatives for enhancement of peak bone mass in adolescence
KR20060058135A (ko) * 2003-09-19 2006-05-29 화이자 프로덕츠 인코포레이티드 골감소증 또는 남성 골다공증의 치료를 위한2-알킬리덴-19-노르-비타민 ｄ 유도체
US7214670B2 (en) * 2003-09-24 2007-05-08 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 to increase the life expectancy of human beings
US7704980B2 (en) * 2003-10-08 2010-04-27 Wisconsin Alumni Research Foundation Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds
US8188064B2 (en) * 2003-11-25 2012-05-29 Wisconsin Alumni Research Foundation Vitamin D analogs for obesity prevention and treatment
US7053075B2 (en) * 2003-11-25 2006-05-30 Deluca Hector F Methods for reducing body fat using vitamin D compounds
US7915242B2 (en) * 2004-02-17 2011-03-29 Wisconsin Alumni Research Foundation Vitamin D receptor antagonists and their use in treating asthma
US7214671B2 (en) * 2004-02-19 2007-05-08 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 for the prophylaxis of bone diseases
US7713951B2 (en) * 2004-04-09 2010-05-11 Wisconsin Alumni Research Foundation 2-alkylidene-18,19-dinor-vitamin D compounds
CA2586679A1 (en) 2004-11-12 2006-05-18 Bioxell Spa Combined use of vitamin d derivatives and anti-proliferative agents for treating bladder cancer
EP1838667A2 (en) * 2004-11-22 2007-10-03 Wisconsin Alumni Research Foundation 2alpha-methyl-19-nor-1alpha-hydroxy-homopregnacalciferol and its uses
US8222235B2 (en) * 2004-11-22 2012-07-17 Wisconsin Alumni Research Foundation 2-methylene-19-nor-(20R)-1α-hydroxy-bishomopregnacalciferol
CA2588415C (en) * 2004-11-22 2012-07-10 Wisconsin Alumni Research Foundation 2-methylene-19,26,27-trinor-(20s)-1-alpha-hydroxyvitamin d3 and its uses
MX2007006544A (es) * 2004-11-22 2007-07-25 Wisconsin Alumni Res Found 2-metilen-18,19-dinor-1a-hidroxi-homopregnacalciferol y sus usos.
WO2006057914A2 (en) * 2004-11-22 2006-06-01 Wisconsin Alumni Research Foundation 2-methylene-19-nor-(20s)-1alpha-hydroxy-trishomopregnacalciferol
ATE469883T1 (de) * 2004-11-22 2010-06-15 Wisconsin Alumni Res Found 2-methylen-19-nor-1alpha-hydroxy-17- enhormopregnacalziferol und anwendungen davon
AU2005309820B2 (en) * 2004-11-22 2011-06-23 Wisconsin Alumni Research Foundation 2-methylene-19,21-dinor-1alpha-hydroxy-bishomopregnacalciferol
US7563783B2 (en) * 2005-02-11 2009-07-21 Wisconsin Alumni Research Foundation 2-methylene-19-nor-(20S-24S)-1α,25-dihydroxyvitamin-D2
DK1848442T3 (da) * 2005-02-11 2012-05-29 Wisconsin Alumni Res Found 2-methylene-19-nor-(20s-24epi)-1alfa,25-dihydroxyvitamine-d2
JP2008538214A (ja) * 2005-03-29 2008-10-16 ウイスコンシン アラムニ リサーチ ファンデーション ２−メチレン−１９−ノル−（２３Ｓ）−２５−デヒドロ−１α−ヒドロキシビタミンＤ３−２６，２３−ラクトンおよび２−メチレン−１９−ノル−（２３Ｒ）−２５−デヒドロ−１α−ヒドロキシビタミンＤ３−２６，２３−ラクトン
US7241909B2 (en) * 2005-05-03 2007-07-10 Wisconsin Alumni Research Foundation 19,26,27-trinor-1α,25-dihydroxyvitamin D3 compounds
EP1931324B1 (en) * 2005-08-30 2015-01-28 Wisconsin Alumni Research Foundation Des-c,d analogs of 1alpha,25-dihydroxy-19-norvitamin d3
US20070066566A1 (en) * 2005-09-22 2007-03-22 Wisconsin Alumni Research Foundation 19,23,24,25,26,27-Hexanor-1alpha-hydroxyvitamin D3
US7803789B2 (en) * 2006-02-02 2010-09-28 Wisconsin Alumni Research Foundation Vitamin D analog—RAK, methods and uses thereof
US7528122B2 (en) * 2006-02-02 2009-05-05 Wisconsin Alumni Research Foundation Vitamin D analog—NEL, methods and uses thereof
JP2009532482A (ja) * 2006-04-05 2009-09-10 ウイスコンシン アラムニ リサーチ ファンデーション １α−ヒドロキシ−２−（３’−ヒドロキシプロピリデン）−１９−ノル−ビタミンＤ化合物類及びそれらの製造及び使用方法
US20090281340A1 (en) * 2006-04-05 2009-11-12 Deluca Hector F 1alpha-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin d compounds and methods of making and treatment thereof
EP2046737B1 (en) * 2006-04-06 2011-09-07 Wisconsin Alumni Research Foundation 2-methylene-1 alpha,25-dihydroxy-19,21-dinorvitamin d3 analogs and uses thereof
MX2008012673A (es) * 2006-04-06 2008-10-15 Wisconsin Alumni Res Found Analogos de 2-metilen-1a-hidroxi-19, 21-dinorvitamina d3 y sus usos.
MX2008012672A (es) * 2006-04-06 2008-10-15 Wisconsin Alumni Res Found Analogos de 2-metilen-1a-hidroxi-18,19,21-trinor vitamina d3 y sus usos.
JP2009533483A (ja) * 2006-04-06 2009-09-17 ウイスコンシン アラムニ リサーチ ファンデーション ２−メチレン−１α，２５−ジヒドロキシ−１８，１９，２１−トリノルビタミンＤ３およびその使用
MX2008012671A (es) * 2006-04-06 2008-10-15 Wisconsin Alumni Res Found Analogos 1 a,25-dihidroxi- 19, 26,27-trinor vitamina d 2-sustituidos y sus usos.
WO2008026078A2 (en) * 2006-04-06 2008-03-06 Wisconsin Alumni Research Foundation 19-nor-vitamin d analogs with 1,2,or 3,2 heterocyclic ring
US8193169B2 (en) * 2006-04-06 2012-06-05 Wisconsin Alumni Research Foundation (20R)-2α-methyl-19,26,2-trinor-vitamin D analogs
US7763598B2 (en) * 2006-04-10 2010-07-27 Wisconsin Alumni Research Foundation 1α-hydroxy-2-(3′-hydroxypropylidene)-19-nor-vitamin D compounds with a 1,1-dimethylpropyl side chain
WO2008039754A1 (en) * 2006-09-28 2008-04-03 Wisconsin Alumni Research Foundation 2-methylene-(20r,25s)-19,27-dinor-(22e)-vitamin d analogs
CA2662864A1 (en) * 2006-09-28 2008-04-03 Wisconsin Alumni Research Foundation 2-methylene-(20s,25s)-19,27-dinor-(22e)-vitamin d analogs
US20080171728A1 (en) * 2007-01-12 2008-07-17 Quatrx Pharmaceuticals Co. Efficient Process for Preparing Steroids and Vitamin D Derivatives With the Unnatural Configuration at C20 (20 Alpha-Methyl) from Pregnenolone
AU2008345085A1 (en) * 2007-12-28 2009-07-09 Wisconsin Alumni Research Foundation 2-methylene-(20S,25S)-19,26-dinor-vitamin D analogs
MX2010007266A (es) * 2007-12-28 2010-11-30 Wisconsin Alumni Res Found Análogos de vitamina d, (20s)-23, 23-difluoro-2-metilen-19-nor-bis homopregnacalciferol.
EP2237837B1 (en) * 2007-12-28 2012-08-22 Wisconsin Alumni Research Foundation (20r)-23,23-difluoro-2-methylene-19-nor-bishomopregnacalciferol-vitamin d analogs
AU2008345084A1 (en) * 2007-12-28 2009-07-09 Wisconsin Alumni Research Foundation 2-methylene-(20S,25R)-19,26-dinor-vitamin D analogs
WO2009086440A1 (en) * 2007-12-28 2009-07-09 Wisconsin Alumni Research Foundation 2-methylene-20-methyl-19,24,25,26,27-pentanor-vitamin d analogs
AU2009206449B2 (en) * 2008-01-22 2014-04-24 Wisconsin Alumni Research Foundation 13,13-Dimethyl-des-C,D analogs of 1alpha, 25-dihydroxy-19-nor-vitamin D3 compounds and topical composition dosage forms and methods of treating skin conditions
US7648974B1 (en) * 2008-07-10 2010-01-19 Wisconsin Alumni Research Foundation 19-nor-vitamin D analogs with 3,2-dihydrofuran ring
US8399439B2 (en) * 2008-07-10 2013-03-19 Wisconsin Alumni Research Foundation 2-methylene-19,26-dinor-(20S,22E,25R)-vitamin D analogs
US7713953B2 (en) * 2008-07-10 2010-05-11 Wisconsin Alumni Research Foundation 2-methylene-(22E)-25-(1-methylene-hexyl)-26,27-cyclo-22-dehydro-19-nor-vitamin D analogs
US7893043B2 (en) 2008-07-10 2011-02-22 Wisconsin Alumni Research Foundation 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-vitamin D analogs
US8222236B2 (en) * 2008-07-10 2012-07-17 Wisconsin Alumni Research Foundation 2-methylene-(20E)-20(22)-dehydro-19-nor-vitamin D analogs
US8193170B2 (en) * 2008-07-10 2012-06-05 Wisconsin Alumni Research Foundation 2-methylene-19,26-dinor-(20R,22E,25R)-vitamin D analogs
US7879829B2 (en) * 2008-07-10 2011-02-01 Wisconsin Alumni Research Foundation 19-nor-vitamin D analogs with 1,2-dihydrofuran ring
US7888339B2 (en) 2008-07-10 2011-02-15 Wisconsin Alumni Research Foundation 2-methylene-20(21)-dehydro-19-nor-vitamin D analogs
NZ595727A (en) * 2009-04-17 2013-11-29 Vidasym Inc Vitamin d receptor agonists and uses thereof
EP2461815B1 (en) * 2009-08-03 2014-10-22 Wisconsin Alumni Research Foundation Method of preventing renal disease and treating symptoms thereof
US8217023B2 (en) * 2009-10-02 2012-07-10 Wisconsin Alumni Research Foundation 19-nor-vitamin D analogs with 1,2- or 3,2-cyclopentene ring
WO2011041599A2 (en) * 2009-10-02 2011-04-07 Wisconsin Alumni Research Foundation 6-methylvitamin d3 analogs and their uses
CA2776462C (en) 2009-10-02 2017-04-18 Wisconsin Alumni Research Foundation (20s,22e)-2-methylene-19-nor-22-ene-1.alpha.,25-dihydroxyvitamin d3 analogs
AU2010300539B9 (en) * 2009-10-02 2018-07-19 Wisconsin Alumni Research Foundation 1-desoxy-2-methylene-19-nor-vitamin D analogs and their uses
CA2777938C (en) 2009-10-21 2017-11-14 Wisconsin Alumni Research Foundation Method of preventing type 1 diabetes
JP5770261B2 (ja) * 2010-03-23 2015-08-26 ウイスコンシン アラムニ リサーチ ファンデーション （２０Ｓ）−２−メチレン−１９−ノル−２２−ジメチル−１α，２５−ジヒドロキシビタミンＤ３および（２０Ｒ）−２−メチレン−１９−ノル−２２−ジメチル−１α，２５−ヒドロキシビタミンＤ３
US8664206B2 (en) 2010-03-23 2014-03-04 Wisconsin Alumni Research Foundation Diastereomers of 2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3
EP2556054B1 (en) * 2010-03-23 2017-09-27 Wisconsin Alumni Research Foundation Diastereomers of 2-methylene-19-nor-22-methyl-1alpha,25-dihydroxyvitamin d3
MX339926B (es) 2010-09-30 2016-06-16 Wisconsin Alumni Res Found * (20r, 25s)-metilen-19,26-dinor-1a,25-dihidroxivitamina d3 en forma cristalina.
WO2012065050A1 (en) 2010-11-12 2012-05-18 Wisconsin Alumni Research Foundation 22-haloacetoxy-homopregnacalciferol analogs and their uses
US9290447B2 (en) 2011-05-03 2016-03-22 Wisconsin Alumni Research Foundation (20R) and (20S)-24-(p-toluenesulfonyloxy)-25,26,27-trinorvitamin D3 analogs and their uses
US8987235B2 (en) 2011-05-17 2015-03-24 Wisconsin Alumni Research Foundation N-cyclopropyl-(20R)-2-methylene-19,26,27-trinor-25-aza-vitamin D analogs and their uses
EP2714656B1 (en) 2011-06-03 2017-05-03 Wisconsin Alumni Research Foundation (22e)-2-methylene-26,27-cyclo-22-dehydro-1alpha-hydroxy-19-norvitamin d3 derivatives
EP2721004B1 (en) * 2011-06-14 2017-07-26 Wisconsin Alumni Research Foundation 3-desoxy-2-methylene-19-nor-vitamin d analogs and their uses
US10479764B2 (en) 2011-06-28 2019-11-19 Wisconsin Alumni Research Foundation 2-methylene-(22E)-25-hexanoyl-24-oxo-26,27-cyclo-22-dehydro-19-nor-vitamin D analogs
US20130178449A1 (en) 2011-07-18 2013-07-11 Wisconsin Alumni Research Foundation 2-Methylene-20(21)-Dehydro-19,24,25,26,27-Pentanor-Vitamin D Analogs
US20130053356A1 (en) 2011-08-26 2013-02-28 Hector F. DeLuca 2-methylene-19,23,24-trinor-1alpha-hydroxyvitamin d3
JP6329901B2 (ja) 2011-08-30 2018-05-23 ウイスコンシン アラムニ リサーチ ファンデーション １α−ヒドロキシ−２０−メチル−２−メチレン−１９，２４，２５，２６，２７−ペンタノルビタミンＤ３の結晶化
US8420839B1 (en) 2011-10-05 2013-04-16 Wisconsin Alumni Research Foundation Crystallization of 1α-hydroxy-2-methylene-18,19-dinor-homopregnacalciferol
US8729054B2 (en) 2011-10-21 2014-05-20 Wisconsin Alumni Research Foundation 3-desoxy-2-methylene-vitamin D analogs and their uses
WO2013059060A1 (en) 2011-10-21 2013-04-25 Wisconson Alumni Research Foundation 2-methylene-vitamin d analogs and their uses
JP6072811B2 (ja) * 2011-10-21 2017-02-01 ウイスコンシン アラムニ リサーチ ファンデーション ２−メチレン−ビタミンｄ類似体およびそれらの使用
US8884039B2 (en) 2012-05-30 2014-11-11 Wisconsin Alumni Research Foundation Crystallization of (20R) and (20S) analogs of 2-methylene-19-nor-24-dimethyl-1α,25-dihydroxyvitamin D3
US8940916B2 (en) * 2012-05-30 2015-01-27 Wisconsin Alumni Research Foundation Crystallization of (20R)-2-methylene-19-nor-24-difluoro-1α,25-dihydroxyvitamin D3
US9040728B2 (en) 2012-05-30 2015-05-26 Wisconsin Alumni Research Foundation Crystallization of (20R) 19-nor-24-difluoro-1α,25-dihydroxyvitamin D3
US9212137B2 (en) 2012-05-30 2015-12-15 Wisconsin Alumni Research Foundation Crystallization of (20R,22R)-2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3 and related precursors
US8785422B2 (en) 2012-06-06 2014-07-22 Wisconsin Alumni Research Foundation A-ring modified 19-nor-vitamin D analogs and their uses
JP2015522015A (ja) 2012-06-29 2015-08-03 ウイスコンシン アラムニ リサーチ ファンデーション 続発性副甲状腺機能亢進症を治療するための２−メチレン−１９−ノル−（２０Ｓ）−１α，２５−ジヒドロキシビタミンＤ３の使用
EP2746252A1 (en) 2012-12-21 2014-06-25 Wisconsin Alumni Research Foundation (WARF) Crystallization of 1alpha-hydroxy-2-methylene- 18,19-dinor-homopregnacalciferol
US9416102B2 (en) * 2013-01-23 2016-08-16 Wisconsin Alumni Research Foundation (22E)-2-methylene-22-dehydro-1α,24,25-trihydroxy-19-nor-vitamin D3 analogs
US10369161B2 (en) 2014-12-30 2019-08-06 Wisconsin Alumni Research Foundation Use of 2-methylene-19-NOR-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism
US9539264B2 (en) 2014-12-30 2017-01-10 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics
US10494337B2 (en) * 2015-05-26 2019-12-03 Wisconsin Alumni Research Foundation (20S)-1-α,25-dihydroxy-24,24-difluoro-19-nor-vitamin D3 analogs and their pharmaceutical uses
US20170296558A1 (en) 2016-04-18 2017-10-19 Wisconsin Alumni Research Foundation Use of 2amd and 2md to treat fibrosis
US10105375B2 (en) 2016-08-30 2018-10-23 Wisconsin Alumni Research Foundation Combination of low dose 2-methylene-19-nor-(20S)1α, 25-dihydroxyvitamin D3 and calcimimetics to treat secondary hyperparathyroidism

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666634A (en) * 1984-12-05 1987-05-19 Chugai Seiyaku Kabushiki Kaisha vitamin D3 derivatives having a substituent at 2-position
US5246925A (en) * 1989-03-09 1993-09-21 Wisconsin Alumni Research Foundation 19-nor-vitamin D compounds for use in treating hyperparathyroidism
NZ232734A (en) * 1989-03-09 1991-11-26 Wisconsin Alumni Res Found 19-nor vitamin d derivatives and pharmaceutical compositions
CA1333616C (en) * 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
US5086191A (en) * 1991-05-28 1992-02-04 Wisconsin Alumni Research Foundation Intermediates for the synthesis of 19-nor vitamin D compounds
AU650751B2 (en) * 1991-05-28 1994-06-30 Wisconsin Alumni Research Foundation Novel synthesis of 19-nor vitamin D compounds
JP3213092B2 (ja) * 1991-11-01 2001-09-25 中外製薬株式会社 ２β位に置換基を有するビタミンＤ誘導体
DE69400495T2 (de) * 1993-04-05 1997-04-30 Wisconsin Alumni Res Found 19-Nor-vitamin-D3-Verbindung mit einem Substituent an die 2. Stelle
US5565589A (en) * 1993-11-03 1996-10-15 Wisconsin Alumni Research Foundation 17-formyl-5,6-trans-vitamin D compounds
US5428029A (en) * 1993-11-24 1995-06-27 Hoffmann-La Roche Inc. Vitamin D3 fluorinated analogs
WO1996001811A1 (en) * 1994-07-11 1996-01-25 The Johns-Hopkins University 2-substituted 1,25-dihydroxyvitamin d3 derivatives

Also Published As

Publication number Publication date
WO1998041501A1 (en) 1998-09-24
EP0970047B1 (en) 2002-09-11
KR20000076306A (ko) 2000-12-26
US5936133A (en) 1999-08-10
NO994398D0 (no) 1999-09-10
AU6280198A (en) 1998-10-12
DK0970047T3 (da) 2002-11-11
ATE223890T1 (de) 2002-09-15
DE69807852T2 (de) 2009-09-24
NZ337503A (en) 2000-09-29
JP2001504135A (ja) 2001-03-27
PT970047E (pt) 2003-01-31
DE69807852D1 (de) 2002-10-17
AU714253B2 (en) 1999-12-23
JP4035144B2 (ja) 2008-01-16
NO322535B1 (no) 2006-10-23
ES2179451T3 (es) 2003-01-16
CA2283829C (en) 2006-07-11
CA2283829A1 (en) 1998-09-24
KR100380914B1 (ko) 2003-04-21
EP0970047A1 (en) 2000-01-12
JP3786713B2 (ja) 2006-06-14
US5843928A (en) 1998-12-01
JP2006117680A (ja) 2006-05-11

Similar Documents

Publication Publication Date Title
DE69807852D1 (de) 2-alkyliden-19-nor-vitamin d-verbindungen
AU4790501A (en) 2-alkylidene-19-nor-vitamin d compounds and their therapeutic uses
DK0971888T3 (da) 2-alkyl-19-nor-vitamin D-forbindelser
CA2403232A1 (en) 26,27-homologated-20-epi-2-alkyl-19-nor-vitamin d compounds
BR9305907A (pt) Uso de derivados de substituída para tratamento de esclerose múltipla
GB9813540D0 (en) Chemical compounds
DE69415690D1 (de) (e)-20(22)-dehydrovitamin-d-verbindungen
DK0667856T3 (da) Nye D-vitaminanaloger
ATE537834T1 (de) 2-methylen-19-nor-vitamin d2-verbindungen
BG108180A (en) Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases
ATE238986T1 (de) 1,3-dihydroxy-20,20-dialkyl-vitamin d3 analoga
ID28365A (id) Turunan produk alami yang baru
BR0010560A (pt) 3-piridil-4-arilpirrois substituìdos e métodos terapêuticos e profiláticos relacionados
DE602005018203D1 (de) Arylalkylsulfonamide als therapeutische mittel zur behandlung von knochenleiden
ATE350043T1 (de) 2-methylen-19-nor-20(s)-25-methyl-1alpha- hydroxycalciferol und seine verwendungen
TH62500A (th) Nk1 แอนทาโกนิสท์

Legal Events

Date Code Title Description
RE Reestablishment of rights (par. 72 patents act)
MK1K Patent expired